DaVita Healthcare Partners traded at $199.52 this Monday May 18th, decreasing $0.22 or 0.11 percent since the previous trading session. Looking back, over the last four weeks, DaVita Healthcare Partners lost 33.61 percent. Over the last 12 months, its price rose by 37.64 percent. Looking ahead, we forecast DaVita Healthcare Partners to be priced at 195.73 by the end of this quarter and at 184.16 in one year, according to Trading Economics global macro models projections and analysts expectations.
DaVita Inc., formerly DaVita HealthCare Partners Inc., operates one division: DaVita Kidney Care (Kidney Care). The Kidney Care division consists of the Company's United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. The Company's segments include U.S. dialysis and related lab services and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as an end-stage renal disease (ESRD). In addition, as of March 31, 2019, the Company operated or provided administrative services to 243 outpatient dialysis centers located in nine countries outside of the United States.